Publications by authors named "Hannah P Sur"
Background: Despite multi-model therapy of maximal surgical resection, radiation, chemotherapy, and tumor-treating fields, the median survival of glioblastoma (GBM) patients is less than 15 months. Protein arginine methyltransferase 5 (PRMT5) catalyzes the symmetric dimethylation of arginine residues and is overexpressed in GBM. Inhibition of PRMT5 causes senescence in stem-like GBM tumor cells.
View Article and Find Full Text PDFArticle Synopsis
- Preclinical models are crucial for studying the immune response to gliomas, and this study focused on comparing fluorescently transfected GL261 murine glioma cells with non-fluorescent versions.
- The research involved implanting mice with different GL261 cell types and assessing their survival rates and immune responses through cytokine profiling.
- Results showed that mice with non-fluorescent GL261 cells had shorter median survival compared to those with fluorescent GL261-Luc2 cells, which also exhibited increased inflammatory cytokines, indicating a stronger anti-tumor immune response.
Immunotherapy is a promising new therapeutic field that has demonstrated significant benefits in many solid-tumor malignancies, such as metastatic melanoma and non-small cell lung cancer. However, only a subset of these patients responds to treatment. Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis of 14.
View Article and Find Full Text PDF